HC Wainwright Issues Positive Forecast for Ocugen (NASDAQ:OCGN) Stock Price

Ocugen (NASDAQ:OCGN) had its price objective lifted by HC Wainwright from $7.00 to $10.00 in a report published on Wednesday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other brokerages have also recently issued reports on OCGN. Canaccord Genuity Group assumed coverage on Ocugen in a research note on Tuesday, March 17th. They issued a “buy” rating and a $12.00 price objective on the stock. Oppenheimer started coverage on Ocugen in a research note on Wednesday, March 11th. They set an “outperform” rating and a $10.00 target price for the company. Chardan Capital restated a “buy” rating and set a $7.00 price target on shares of Ocugen in a report on Thursday, March 5th. Wall Street Zen raised Ocugen from a “sell” rating to a “hold” rating in a research report on Saturday, March 21st. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Ocugen in a research note on Thursday, January 22nd. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $9.75.

Ocugen Trading Up 1.6%

Shares of OCGN stock opened at $1.95 on Wednesday. Ocugen has a fifty-two week low of $0.57 and a fifty-two week high of $2.73. The company has a 50 day moving average price of $1.73 and a 200 day moving average price of $1.53. The stock has a market capitalization of $639.41 million, a P/E ratio of -8.48 and a beta of 2.75. The company has a debt-to-equity ratio of 8.04, a quick ratio of 1.06 and a current ratio of 1.06.

Ocugen (NASDAQ:OCGN) last released its earnings results on Wednesday, March 4th. The company reported ($0.06) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.06). Ocugen had a negative net margin of 1,192.18% and a negative return on equity of 2,626.38%. The company had revenue of ($0.19) million for the quarter, compared to analyst estimates of $0.86 million. Equities research analysts predict that Ocugen will post -0.2 EPS for the current fiscal year.

Hedge Funds Weigh In On Ocugen

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd raised its holdings in Ocugen by 76,831.8% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 82,317 shares of the company’s stock worth $111,000 after purchasing an additional 82,210 shares in the last quarter. Virtu Financial LLC purchased a new stake in shares of Ocugen during the 4th quarter worth approximately $106,000. NewEdge Advisors LLC boosted its holdings in shares of Ocugen by 69.0% in the 4th quarter. NewEdge Advisors LLC now owns 135,460 shares of the company’s stock valued at $183,000 after buying an additional 55,305 shares in the last quarter. Millennium Management LLC grew its position in shares of Ocugen by 29.7% in the 4th quarter. Millennium Management LLC now owns 5,396,417 shares of the company’s stock valued at $7,285,000 after buying an additional 1,234,268 shares during the last quarter. Finally, Balyasny Asset Management L.P. purchased a new position in shares of Ocugen in the 4th quarter valued at $196,000. 10.27% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Ocugen

Here are the key news stories impacting Ocugen this week:

• Positive Sentiment: Topline Phase 2 ArMaDa data: the optimal OCU410 dose showed a 31% reduction in GA lesion growth at 12 months, structural preservation signals, no OCU410-related serious adverse events, and a plan to start Phase 3 in Q3 2026 — a clear clinical milestone that supports a sizeable long-term value case. Ocugen Announces Topline 12-month Data (GlobeNewswire)
• Positive Sentiment: Analyst support: HC Wainwright raised its price target to $10 (Buy) and Chardan reaffirmed a Buy with a $7 target — both indicate sizable upside expectations based on the Phase 2 readout and anticipated Phase 3. Benzinga analyst coverage
• Positive Sentiment: Balance-sheet commentary: recent coverage highlights Ocugen’s healthy cash position and manageable operating spend, which reduces near-term financing risk as the company advances OCU410 toward Phase 3. OCGN Has A Healthy Cash Position (Yahoo Finance)
• Neutral Sentiment: Company call/transcript and analyses are available for deeper read-throughs of subgroup data and safety details; these will matter to investors assessing Phase 3 design and market potential. Phase II transcript (Seeking Alpha)
• Neutral Sentiment: Third-party summaries (Quiver/others) reiterate the 31% result and highlight potential advantages vs. current therapies, but note forward-looking uncertainty — helpful context but not fresh catalysts. QuiverQuant summary
• Neutral Sentiment: Short-interest reports in recent feeds showed anomalous/zero values and NaN changes — data appears unreliable; treat reported short-interest moves with caution until exchanges publish confirmed figures.
• Negative Sentiment: Market reaction and critical headlines: some outlets framed the Phase 2 results as “lagging” earlier expectations (reporting the outcome as smaller than prior hints), which prompted selling pressure and short-term underperformance. Ocugen Falls — Yahoo
• Negative Sentiment: Additional negative headlines and analyst caution: Zacks and MarketWatch/other outlets highlighted the stock drop and framed the release as a mixed outcome — media focus on the “tanks/falls” narrative amplified volatility despite the statistically significant primary endpoint. Ocugen Falls — Zacks

Ocugen Company Profile

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.

In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.